WOW.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Wirecutter (website) - Wikipedia

   en.wikipedia.org/wiki/Wirecutter_(website)

   Wirecutter (formerly known as The Wirecutter) is a product review website owned by The New York Times Company. It was founded by Brian Lam in 2011 and purchased by The New York Times Company in 2016 for about $30 million.

3. Comparing Online Review Sites for Better Results - AOL

   www.aol.com/comparing-online-review-sites-better...

   Comparing Online Review Sites for Better Results. kmcdill@aol.com (Kent McDill) September 9, 2021 at 7:00 AM. We all do a great deal of shopping sight unseen. We love to go to new bars and ...

4. Opinion - FTC rules on fake reviews aren’t enough: Hold sites ...

   www.aol.com/opinion-ftc-rules-fake-reviews...

   Review-sellers on Instagram regularly recruit Yelp Elites, Yelp’s most trusted and prestigious reviewers, and pay them $20 to $50 to post pre-written Yelp reviews of businesses.

5. Reviewed (website) - Wikipedia

   en.wikipedia.org/wiki/Reviewed_(website)

   Reviewed is a consumer product review website based in Cambridge, Massachusetts and emphasizes a science-based approach that tests consumer products in both everyday and lab environments. [1] As of 2021, Reviewed has over 70 employees and over 40 staff members dedicated to testing products. The site is owned by Gannett and part of the USA Today ...

6. PowerReviews - Wikipedia

   en.wikipedia.org/wiki/PowerReviews

   The company's software allows product ratings and reviews, answering customer questions, product sampling, images, videos, and social content, and analytics tools to examine the impact of user-generated content and to benchmark product performance. PowerReviews is headquartered in Chicago with an office in London.

7. Lisata Therapeutics Announces First Patient Treated in the ...

   lite.aol.com/tech/story/0022/20240917/9231387.htm

   BASKING RIDGE, N.J., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced treatment of the first patient in the second-line cholangiocarcinoma (“CCA”) cohort of the BOLSTER ...